# DESCRIPTION

## GOVERNMENT FUNDING

- acknowledge government funding

## TECHNICAL FIELD

- introduce C9orf46 homolog and Plg-RKT

## BACKGROUND

- motivate plasminogen binding
- summarize cell surface proteolysis
- describe plasminogen binding sites
- discuss carboxyl terminal lysines
- introduce CpB-sensitive plasminogen receptors
- describe limitations of prior art
- motivate search for integral membrane protein

## BRIEF SUMMARY OF THE INVENTION

- introduce Plg-RKT and its function
- describe contemplated Plg-RKT polypeptides and antibodies

## DETAILED DESCRIPTION OF THE INVENTION

### A. Definitions

- define amino acid residue
- define antibody and related terms
- define lipoprotein(a) and related terms
- define polypeptide and related terms

### B. Polypeptides

- define Plg-RKT polypeptide
- describe Plg-RKT molecule
- specify SEQ ID NO: 1
- introduce first embodiment
- specify SEQ ID NO: 2
- introduce second embodiment
- specify SEQ ID NO: 3
- introduce third embodiment
- specify SEQ ID NO: 4
- introduce multiple related embodiments
- specify multiple SEQ ID NOs
- conclude multiple related embodiments
- define Plg-RKT polypeptide
- specify preferred Plg-RKT polypeptides
- describe immunological mimicry
- outline polypeptide requirements
- define analogs and chemical derivatives
- describe conservative substitutions
- outline fragment and linker definitions
- discuss terminal modifications
- describe antigenically related variants
- outline pharmaceutically acceptable salts
- describe synthesis methods

### C. Antibodies and Monoclonal Antibodies

- define antibody
- define antibody combining site
- describe antibody molecule
- introduce Fab, Fab′, F(ab′)2 and F(v) portions
- describe preparation of Fab and F(ab′)2 portions
- describe anti-Plg-RKT antibody
- characterize anti-Plg-RKT antibody
- describe immunoreactivity of anti-Plg-RKT antibody
- define substantially free
- describe production of anti-Plg-RKT antibody
- describe purification of anti-Plg-RKT antibody
- introduce inoculum
- describe preparation of inoculum
- describe conjugation of polypeptide to carrier
- introduce monoclonal antibody
- describe production of monoclonal antibody

### D. Diagnostic Systems

- contemplate diagnostic system
- include Plg-RKT polypeptide and/or antibody
- define package
- describe instructions for use
- include label or indicating means
- define complex
- describe labeling means
- exemplify fluorescent labeling agents
- describe enzyme labeling agents
- describe radioactive labeling agents
- describe linking of labels
- include specific binding agent
- describe specific binding agent
- describe ELISA format
- affix reagent to solid matrix
- describe solid matrices
- provide reagent species in solution or dry form
- describe packaging materials
- contemplate method for detecting inflammation
- contemplate method for detecting cancer
- contemplate method for identifying patients at risk
- contemplate method for detecting hematologic disorders

### E. Assay Methods

- introduce immunoassay methods
- describe heterogeneous and homogeneous protocols
- outline steps of assay method
- form immunoreaction admixture
- maintain biological assay conditions
- determine amount of Plg-RKT polypeptide-containing immunoreaction product
- describe competitive assay methods
- outline detection means
- describe cell separation medium
- outline methods for detecting expression of Plg-RKT
- describe direct detection methods

### F. Therapeutic Compositions

- introduce therapeutic compositions
- describe physiologically tolerable carrier
- outline preparation of pharmacological composition
- describe pharmaceutically acceptable salts

### G. Therapeutic Methods

- introduce therapeutic methods
- describe inhibition of plasminogen binding to Plg-RKT
- outline method for blocking binding of plasminogen to Plg-RKT
- describe therapeutically effective amount of Plg-RKT polypeptide
- outline administration of therapeutic composition
- describe unit dose
- outline regimes for initial administration and booster shots
- describe composition comprising Plg-RKT polypeptide
- outline composition comprising antibody

## EXAMPLES

- introduce isolation of Plg-RKT
- describe biotinylation of cells
- detail membrane fraction preparation
- outline plasminogen-Sepharose affinity column procedure
- describe MudPIT analysis
- identify C9orf46 homolog/Plg-RKT protein
- discuss carboxyl-terminal lysine importance
- describe amino acid sequence of Plg-RKT
- detail cell and tissue distribution of Plg-RKT
- test plasminogen binding to carboxyl-terminal peptide
- raise antiserum against synthetic peptide
- detect upregulation of Plg-RKT in M-CSF treated cells
- test partitioning of Plg-RKT to detergent phase
- raise monoclonal antibody against Plg-RKT polypeptide
- inhibit plasminogen binding with monoclonal antibody
- inhibit cell surface plasminogen activation
- test inhibitory Plg-RKT polypeptides
- recognize Plg-RKT by plasminogen fragments
- raise monoclonal antibody against rat Plg-RKT polypeptide
- distinguish breast cancer cells from normal tissue
- detect Plg-RKT expression in infiltrating ductal carcinoma

